Cite
Correction to "1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases.". J Pharmacol Exp Ther. 2016;358(1):1-2doi: 10.1124/jpet.115.170120err.
(2016). Correction to "1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases.". The Journal of pharmacology and experimental therapeutics, 358(1), 1-2. https://doi.org/10.1124/jpet.115.170120err
"Correction to "1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases."." The Journal of pharmacology and experimental therapeutics vol. 358,1 (2016): 1-2. doi: https://doi.org/10.1124/jpet.115.170120err
Correction to "1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases.". J Pharmacol Exp Ther. 2016 Jul;358(1):1-2. doi: 10.1124/jpet.115.170120err. PMID: 27278809.
Copy
Download .nbib
